Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with metastatic and/or advanced solid tumors or lymphomas not amenable to curative treatment by surgery.
Histologically documented advanced or metastatic solid tumors or lymphomas
Must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening
ECOG Performance Status ≤ 2.
You may not be if
Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery).
Patients diagnosed with T-cell Lymphomas.
Patients with prior allogenic transplants.
Patients previously treated with anti-GITR therapy.
History of severe hypersensitivity reactions to other mAbs.
Patients intolerant to prior immunotherapy (unable to continue/receive due to immune-related AE).
Clareo Health | Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
